Skip to content
Calculator
Guide

DSIP (emideltide): why the FDA committee rejected the sleep peptide

Last updated: November 4, 2026 · 4 min read · By the Grey Peptides Editorial Board

A serene young woman peacefully sleeping on a white pillow indoors at night
Photo by Polina ⠀ on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • DSIP was the only one of seven peptides the FDA's compounding committee voted against in July 2026, by 6 to 7 with one abstention, agreeing with the FDA's own staff 12 13 11.
  • Its sleep evidence is a handful of small intravenous trials from the 1980s and 1990s that disagree with each other: one positive seven-night study in insomnia, others judging the effects weak or of little clinical significance 4 5 6.
  • A 2006 review called DSIP "a still unresolved riddle", partly because no gene, protein or receptor for it had been isolated 2. FDA found it registered as a drug in no country it searched 1.

A sleep factor that was never pinned down

Delta sleep-inducing peptide Medium, given the name emideltide in FDA's documents, is nine amino acids long: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu 1. It was isolated by a Basel group in 1977 from rabbit cerebral venous blood as a candidate sleep factor. A 2006 review titled it "a still unresolved riddle": its link to sleep had never been further characterised, in part because the DSIP gene, protein and any related receptor had not been isolated 2.

What the sleep trials found

The first human study looked promising. Six healthy volunteers given a slow intravenous infusion in a double-blind crossover reported sleep pressure almost at once, and total sleep within 130 minutes rose by a median of 59% against placebo 3. The most positive patient study followed: 14 middle-aged people with chronic insomnia received injections for seven nights under double-blind, placebo-controlled conditions, and their night sleep improved from the first dose 4.

Other trials were less kind. In a crossover study of insomniac patients over four nights, awakenings and waking time fell, but not significantly against placebo, and the authors judged the effect of little clinical significance 5. In 16 chronic insomniacs studied in a sleep laboratory, sleep efficiency was higher and sleep onset faster with DSIP, but the authors judged the significant effects weak, possibly due in part to a chance change in the placebo group, and concluded that short-term DSIP treatment of chronic insomnia "is not likely to be of major therapeutic benefit" 6. Every one of these trials gave DSIP intravenously; FDA's review found no data for the under-the-skin route nominated for compounding 1.

Where the mechanism ideas went

Earlier work had reported that DSIP inhibits the release of the stress hormone ACTH 7. When this was tested directly in healthy young men, intravenous DSIP left ACTH and cortisol responses almost identical to placebo 7, and in healthy women it had no effect on growth hormone or prolactin 8. In 24 women given anaesthesia, a randomised trial testing whether it would deepen anaesthesia found the opposite of the hypothesis: heart rate rose and anaesthesia seemed lighter 9. And in cats, DSIP reduced sleep, cutting light slow-wave and REM sleep, again the reverse of its name 10.

None of this rules out an effect on sleep in some people. It does mean the mechanism ideas about stress hormones, growth hormone and deep sleep have each been tested at least once and not confirmed: in the four-night insomnia trial, slow-wave sleep did not change 5.

Why the committee said no (as of October 27, 2026)

DSIP was one of seven peptides the FDA's Pharmacy Compounding Advisory Committee considered on July 23 and 24, 2026, for the list of substances pharmacies may compound under section 503A. FDA staff proposed adding none of the seven 11. The committee recommended six of them anyway, but on emideltide it agreed with the staff and voted it down, 6 to 7 with one abstention, as reported (FDA has posted no tallies) 12 13 14. FDA's briefing found evidence that emideltide has been used in compounding since at least 2018, but judged the data too limited to inform its historical use, and concluded that the criteria weigh against listing it 1.

A rejection by the committee is advice too. FDA calls its committees' recommendations non-binding 14. In practice the vote leaves DSIP where it was: not on the 503A list, and not a component of any FDA-approved drug 1. Our PCAC page sets out all seven votes.

On October 30, 2026, HHS, FDA's parent department, published a non-binding policy saying it will not take enforcement action against 503A pharmacy compounding of the six peptides the committee backed, under set conditions 15. DSIP (emideltide) is not among them, and FDA has added none of the six to the 503A Bulks List or Category 1 (our fact check).

Frequently asked questions

Does DSIP help you sleep?

The evidence is mixed and old. One small seven-night trial in insomnia was positive; other small trials found the effects weak or of little clinical significance. FDA's 2026 review discussed seven insomnia publications, all small and all intravenous.

Why did the FDA committee reject DSIP?

On July 24, 2026 the compounding committee voted 6 to 7, with one abstention, against adding emideltide to the 503A list, agreeing with FDA staff, who had proposed against all seven peptides reviewed.

What is emideltide?

The international nonproprietary name for delta sleep-inducing peptide (DSIP), a nine-amino-acid peptide first isolated in 1977.

Is DSIP approved?

No. FDA's 2026 briefing says it is not a component of any FDA-approved drug and is not a registered drug in any country FDA searched, and it is not on the FDA's 503A compounding list.

Sources

  1. US FDA. Emideltide briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 11, 2026): sequence, registration status, clinical studies, historical use and FDA's position. Read October 27, 2026. FDA
  2. Kovalzon, V. M., et al. (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem, 97(2), 303-9. PMID: 16539679
  3. Schneider-Helmert, D., et al. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol, 19(8), 341-5. PMID: 6895513
  4. Schneider-Helmert, D. (1987). Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol, 27(2), 120-9. PMID: 3622582
  5. Monti, J. M., et al. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res, 7(2), 105-10. PMID: 3583493
  6. Bes, F., et al. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology, 26(4), 193-7. PMID: 1299794
  7. Späth-Schwalbe, E., et al. (1995). Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology, 20(3), 231-7. PMID: 7777652
  8. Giusti, M., et al. (1993). Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology, 18(1), 79-84. PMID: 8475226
  9. Pomfrett, C. J., et al. (2009). Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol, 26(2), 128-34. PMID: 19142086
  10. Sommerfelt, L. (1985). Reduced sleep in cats after intraperitoneal injection of delta-sleep-inducing peptide (DSIP). Neurosci Lett, 58(1), 73-7. PMID: 3840239
  11. US FDA. Briefing document introduction, Pharmacy Compounding Advisory Committee, July 23-24, 2026: FDA proposes that each of the seven substances, free base and acetate, not be included on the 503A Bulks List. Read October 27, 2026. FDA
  12. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
  13. Eglovitch, J. S. FDA advisory committee backs two more peptides, rejects one for compounding list. RAPS Regulatory Focus (trade press), July 24, 2026: emideltide 6-7 with one abstention. Read October 27, 2026. Cited without a link.
  14. US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026: briefing documents; no minutes or vote tallies posted (content current as of August 6, 2026; 'Advisory committees make non-binding recommendations'); 503A list (updated May 14, 2026) re-read October 27, 2026: none of the six recommended peptides in Category 1. FDA
  15. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead